Published: October 2018

Last updated: October 2018

Chapter 20: The Mechanics of Basic Health Economics

Health economics allows decision-makers to identify the most efficient allocation of limited resources. It involves measuring the benefits of different health care interventions in such a way that they can be compared across the whole health system. Quality-adjusted life years (QALYS) allow us to measure the benefires that acrue from both increased length of life (i.e. life expectancy) and improved quality of life – or even a combination of both. Once we have estimated the QALYS gains from a particular intervention, these can be compared against the QALYS that must be lost elsewhere in the health system in order to release funds to pay for a new intervention. If the QALY gains from a new intervention outweigh the opportunity costs of moving that money form where it is currently spent, then the health care system as a whole will benefit from the new intervention.

You may also be interested in

Peer-reviewed publication

Reducing Opioid Use for Chronic Pain With a Group-Based Intervention: Economic Evaluation using Randomised Controlled Trial Data

YHEC authors: Joe Moss
Publication date: October 2026
Journal: Addiction

Abstract

BACKGROUND AND AIMS: Long-term strong opioid use for chronic non-malignant pain (CNMP) represents a significant public health challenge, associated with reduced health-related quality of life (HRQoL) and increased mortality. The...

Peer-reviewed publication

Methods in Systematic Reviews of Health Economic Evaluations in Submissions to Health Technology Assessment Agencies: How Systematic Are They, and Does This Matter?

YHEC authors: Chris Bartlett, Rachael McCool, Matthew Taylor
Publication date: October 2026
Journal: PharmacoEconomics

Abstract

Systematic reviews of health economic evaluations (SR-HEEs) are perceived as mandatory components of the health technology assessment (HTA) process in many jurisdictions. However, HTA agencies vary in how they prescribe...

Peer-reviewed publication

Commentary: Selpercatinib versus Multi-Kinase Inhibitors for Advanced Medullary Thyroid Cancer: A Network Meta-Analysis of RET-Targeted Therapies

YHEC authors: Joe Moss, Erin Barker
Publication date: October 2026
Journal: Frontiers in Endocrinology

Abstract

We have read with great interest the published network meta-analysis (NMA) by Wang et al. (2026) in Frontiers in Endocrinology, which synthesised available randomised controlled trial (RCT) evidence to evaluate...